Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
66 hedge funds and large institutions have $135M invested in Osiris Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 10 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
24% more capital invested
Capital invested by funds: $109M → $135M (+$26.3M)
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% less funds holding
Funds holding: 67 → 66 (-1)
94% less call options, than puts
Call options by funds: $404K | Put options by funds: $7.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.68M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$1.27M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.17M |
| 4 |
QI
QS Investors
New York
|
+$874K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$860K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.88M |
| 2 |
Renaissance Technologies
New York
|
-$1.16M |
| 3 |
HNB
Huntington National Bank
Columbus,
Ohio
|
-$1.03M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$991K |
| 5 |
Barclays
London,
United Kingdom
|
-$461K |
OSIR Hedge Fund Activity: Q4 2014 in Review
66 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2014, worth a combined $135M — up 24% from $109M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OSIR positions and 10 closed out — a net gain of 1 holder — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.68M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.88M sold.
- 66 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2014, down from 67 in Q3 2014.
- Funds reported $135M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2014, up 24% quarter-over-quarter.
- 11 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2014 and 10 closed out, a net change of +1 holder.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2014 was Susquehanna International Group, an estimated $2.68M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2014 was Deerfield Management, an estimated $4.88M sold.
Based on aggregated 13F filings for Q4 2014.